


Pre-clinical study demonstrates that the Pressure-Enabled Drug Delivery™ (PEDD™) approach with a TriNav® Infusion System significantly improved intra-arterial delivery of embolic microspheres compared to a traditional microcatheter (TMC).¹

Tumor Penetration

227%


increase in microsphere penetration into the tumor via PEDD (n=16, p=0.029)




Tumor-to-Normal Ratio

PEDD improved the mean T:N ratio from

2.7 to 4.2



Microsphere Intensity In and Around Tumor Tissue



Study Methods:

- Transgenic pigs (Oncopigs) had induced tumors which measured 1-3cm.
- Fluorescently labeled microspheres (100–300 μm Embospheres, Merit Medical) were delivered via hepatic arterial infusion using standard embolization techniques.
- Livers were collected immediately after dosing, and a specialized imaging tool was used to detect microsphere fluorescent signal in and around tumors.
- A blinded quantitative analysis of signal intensity was performed.

The TriNav Infusion System was shown to significantly increase tumor penetration of embolic microspheres with improved sparing of normal liver tissue.

1. Jaroch DB, Liu Y, Kim AY, Katz SC, Cox BF, Hullinger TG. Pressure-Enabled Drug Delivery Significantly Increases Intra-Arterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Model. *J Vasc Interv Radiol* 2025;36:499-504, e1

This summary is sponsored by TriSalus Life Sciences®. Results are not predictive of outcomes in other cases.

INDICATIONS FOR USE: The TriNav Infusion System is intended for use in angiographic procedures. It delivers radiopaque media and therapeutic agents to selected sites in the peripheral vascular system.

CONTRAINDICATIONS: TriNav is not intended for use in the vasculature of the central nervous system (including the neurovasculature) or central circulatory system (including the coronary vasculature).

Rx ONLY. For the safe and proper use of the TriNav device, refer to the Instructions for Use.